Document is current
Any future updates will be listed below
-
Authors
Hieromnimon, Hanna M.
Dolezal, James
Doytcheva, Kristina
Howard, Frederick M.
Kochanny, Sara
Zhang, Zhenyu
Grossman, Robert L.
Tanager, Kevin
Wang, Cindy
Kather, Jakob Nikolas
Izumchenko, Evgeny
Cipriani, Nicole A.
Fertig, Elana J.
Pearson, Alexander T.
Riesenfeld, Samantha J.
-
Funding
Funding for this research was provided by:
National Institute of Biomedical Imaging and Bioengineering T32 training grant (5 T32 EB 9412-13)
Microsoft Research PhD Fellowship
Kura Oncology
Cancer Research Foundation Young Investigator Award
- License Information
-
More Information
Article History
Received: 14 June 2024
Accepted: 24 June 2025
First Online: 7 August 2025
Declarations
:
: Not applicable.
: Not applicable.
: The authors report no disclosures relating to this work. Dr. Pearson participates in advisory boards for Elevar, Ayala, Prelude, and Privo, consults for Abbvie, and receives research funds from Kura, EMD Serono, and the Abbvie-University of Chicago Joint Steering Committee. Dr. Fertig is on the scientific advisory board for Resistance Bio, consults for Mestag Therapeutics and Merck, and receives research funds from Abbvie and Roche/Genetech. JNK declares consulting services for Owkin, France, DoMore Diagnostics, Norway, Panakeia, UK, Scailyte, Switzerland, Cancilico, Germany, Mindpeak, Germany, MultiplexDx, Slovakia, and Histofy, UK; furthermore he holds shares in StratifAI GmbH, Germany, has received a research grant by GSK, and has received honoraria by AstraZeneca, Bayer, Eisai, Janssen, MSD, BMS, Roche, Pfizer and Fresenius.
